Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NuVasive Replaces CFO In Wake Of Poor Q2

Executive Summary

Spine firm NuVasive has named Rajesh Asarpota as the company's new executive vice president and chief financial officer. He steps in after the previous CFO left following NuVasive's disappointing Q2 2017 results.

You may also be interested in...



Earnings Winners & Losers: Orthopedics Firms, JNJ, NUVA, SNN, SYK, ZBH

With earnings reporting season now in full swing, Medtech Insight highlights which companies have exceeded expectations and which ones continue to see their bottom-line sink. This edition throws the spotlight on some of the notable players in the orthopedics space.

Mallinckrodt pursues core quest with Questcor merger

Just nine months after spinning out from Covidien, Mallinckrodt is maintaining its ambition to grow its speciality pharma business aggressively with the planned $5.6bn merger with Questcor Pharmaceuticals. The announcement came only weeks after Mallinckrodt closed its $1.3bn acquisition of Cadence Pharmaceuticals (www.scripintelligence.com, 12 February 2014) and continues to fulfil the commitment Mark Trudeau, Mallinckrodt’s president and CEO, made to investors and analysts last fall.

Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio

Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT105314

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel